ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
Radiopharmaceuticals Expert Joins Lineup for ASNC’s May 5 Congressional Briefing on Improving Access to Cardiac Imaging
Etienne Montagut, president and CEO of PharmaLogic, will present at ASNC’s upcoming…
ASNC Signs onto Effort to End Immigration Processing Delays for International Medical Graduates
ASNC joined the American Academy of Family Physicians and 22 other national…
CMS Phasing Out Fax Machines, Setting New Standards for Claims Documentation
The Centers for Medicare & Medicaid Services (CMS) has released a final…

